ATE249462T1 - Neue kristalline form von n-(4-(2-(2-amino-4,7- dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5- yl)ethyl)benzoyl)-l-glutaminsäure und verfahren für ihre herstellung - Google Patents

Neue kristalline form von n-(4-(2-(2-amino-4,7- dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5- yl)ethyl)benzoyl)-l-glutaminsäure und verfahren für ihre herstellung

Info

Publication number
ATE249462T1
ATE249462T1 AT01906554T AT01906554T ATE249462T1 AT E249462 T1 ATE249462 T1 AT E249462T1 AT 01906554 T AT01906554 T AT 01906554T AT 01906554 T AT01906554 T AT 01906554T AT E249462 T1 ATE249462 T1 AT E249462T1
Authority
AT
Austria
Prior art keywords
pyrrolo
pyrimidine
dihydro
benzoyl
oxo
Prior art date
Application number
AT01906554T
Other languages
English (en)
Inventor
Erik Christopher Chelius
Susan Marie Reutzel-Edens
Sharon Van Den Berghe Snorek
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE249462(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE249462T1 publication Critical patent/ATE249462T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT01906554T 2000-02-25 2001-02-12 Neue kristalline form von n-(4-(2-(2-amino-4,7- dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5- yl)ethyl)benzoyl)-l-glutaminsäure und verfahren für ihre herstellung ATE249462T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25
PCT/US2001/001229 WO2001062760A2 (en) 2000-02-25 2001-02-12 A NOVEL CRYSTALLINE FORM OF N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR

Publications (1)

Publication Number Publication Date
ATE249462T1 true ATE249462T1 (de) 2003-09-15

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01906554T ATE249462T1 (de) 2000-02-25 2001-02-12 Neue kristalline form von n-(4-(2-(2-amino-4,7- dihydro-4-oxo-3h-pyrrolo(2,3-d)-pyrimidin-5- yl)ethyl)benzoyl)-l-glutaminsäure und verfahren für ihre herstellung

Country Status (35)

Country Link
US (1) US7138521B2 (de)
EP (1) EP1259513B1 (de)
JP (1) JP4846158B2 (de)
KR (1) KR100744917B1 (de)
CN (1) CN1183135C (de)
AR (1) AR029471A1 (de)
AT (1) ATE249462T1 (de)
AU (1) AU777047B2 (de)
BR (1) BR0108604A (de)
CA (1) CA2400155C (de)
CO (1) CO5261585A1 (de)
CZ (1) CZ303772B6 (de)
DE (1) DE60100750T2 (de)
DK (1) DK1259513T3 (de)
DZ (1) DZ3283A1 (de)
EA (1) EA004684B1 (de)
EG (1) EG24073A (de)
ES (1) ES2206403T3 (de)
HR (1) HRP20020701B1 (de)
HU (1) HU229704B1 (de)
IL (2) IL150480A0 (de)
MX (1) MXPA02008242A (de)
MY (1) MY124784A (de)
NO (1) NO323422B1 (de)
NZ (1) NZ519796A (de)
PE (1) PE20011082A1 (de)
PL (1) PL208061B1 (de)
PT (1) PT1259513E (de)
SI (1) SI1259513T1 (de)
SK (1) SK287375B6 (de)
SV (1) SV2002000321A (de)
TW (1) TWI237024B (de)
UA (1) UA72791C2 (de)
WO (1) WO2001062760A2 (de)
ZA (1) ZA200205265B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
AU2006311820A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and erlotinib for treating cancer
JP2009514889A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
DE602007011384D1 (de) * 2006-08-14 2011-02-03 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure
KR101045616B1 (ko) * 2006-08-14 2011-07-01 시코르, 인크. 페메트렉세드 이산의 결정형 및 이의 제조 방법
KR20090052355A (ko) 2006-08-14 2009-05-25 시코르, 인크. 순도가 높은 페메트렉세드 이산 및 이의 제조 방법
WO2008021385A2 (en) 2006-08-14 2008-02-21 Sicor Inc. Processes for preparing intermediates of pemetrexed
CA2667348A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using saha and bortezomib for treating multiple myeloma
MX2009010568A (es) * 2007-04-03 2009-10-22 Reddys Lab Ltd Dr Formas solidas de pemetrexed.
CN101417998B (zh) * 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
US20090181990A1 (en) * 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
WO2010028105A2 (en) * 2008-09-08 2010-03-11 Dr. Reddy's Laboratories Ltd. Amorphous pemetrexed disodium
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
EP2504341A1 (de) 2009-11-24 2012-10-03 Azad Pharmaceutical Ingredients AG Neue kristalline form von pemetrexed-dinatrium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
CA2827455C (en) * 2011-03-25 2017-10-24 Scinopharm Taiwan Ltd Process for the production of a pemetrexed salt
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Crystalline pemetrexed dipotassium process
ZA201400898B (en) 2013-02-06 2015-12-23 Cipla Ltd Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
US20160051679A1 (en) 2013-04-12 2016-02-25 Actavis Group Ptc Ehf. Pemetrexed Formulation
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
US20160145260A1 (en) 2013-06-14 2016-05-26 Synthon B.V. Stable pemetrexed arginine salt and compositions comprising it
WO2015008221A1 (en) 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
JP6313317B2 (ja) 2013-10-03 2018-04-18 富士フイルム株式会社 注射液製剤及びその製造方法
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
CA2962383C (en) * 2014-10-30 2019-10-08 Scinopharm Taiwan, Ltd. Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
WO2019073482A1 (en) * 2017-10-10 2019-04-18 Sun Pharmaceutical Industries Limited INTRAVENOUS INFUSION TYPE DOSAGE FORM FOR PETREXED
EP3749311A4 (de) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC Gamma-polyglutamatiertes pemetrexed und verwendungen davon
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
WO2025244944A1 (en) * 2024-05-20 2025-11-27 Opna Bio SA Crystal forms of an agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) * 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
CA2263907A1 (en) * 1996-08-30 1998-03-05 Christopher Leighon Jordan Nonclassical pyrrolo[2,3-d]pyrimidine antifolates
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
CN1246295C (zh) * 1997-09-26 2006-03-22 伊莱利利公司 用于制造抗叶酸剂的方法和中间体
EP1212325A2 (de) * 1999-08-23 2002-06-12 Eli Lilly And Company Neue kristalline form von disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic säuresalz und verfahren hierfür

Also Published As

Publication number Publication date
MY124784A (en) 2006-07-31
AU777047B2 (en) 2004-09-30
NO20023974D0 (no) 2002-08-21
SK11862002A3 (sk) 2003-01-09
EA004684B1 (ru) 2004-06-24
JP4846158B2 (ja) 2011-12-28
PL356423A1 (en) 2004-06-28
DE60100750D1 (de) 2003-10-16
PT1259513E (pt) 2004-02-27
US20030216416A1 (en) 2003-11-20
IL150480A0 (en) 2002-12-01
NO323422B1 (no) 2007-04-30
UA72791C2 (uk) 2005-04-15
PL208061B1 (pl) 2011-03-31
EA200200905A1 (ru) 2003-02-27
EP1259513B1 (de) 2003-09-10
KR20020075449A (ko) 2002-10-04
DE60100750T2 (de) 2004-07-29
CZ303772B6 (cs) 2013-05-02
NO20023974L (no) 2002-08-21
WO2001062760A2 (en) 2001-08-30
DK1259513T3 (da) 2004-01-12
PE20011082A1 (es) 2001-10-22
SV2002000321A (es) 2002-07-16
CO5261585A1 (es) 2003-03-31
HU229704B1 (en) 2014-05-28
CN1406238A (zh) 2003-03-26
HRP20020701B1 (en) 2011-02-28
US7138521B2 (en) 2006-11-21
CA2400155A1 (en) 2001-08-30
KR100744917B1 (ko) 2007-08-01
TWI237024B (en) 2005-08-01
DZ3283A1 (fr) 2001-08-30
NZ519796A (en) 2003-01-31
WO2001062760A3 (en) 2001-12-06
MXPA02008242A (es) 2002-11-29
EG24073A (en) 2008-05-11
SI1259513T1 (en) 2003-12-31
AU3445101A (en) 2001-09-03
HUP0204232A2 (hu) 2003-04-28
HRP20020701A2 (en) 2003-12-31
ZA200205265B (en) 2003-11-11
BR0108604A (pt) 2002-11-19
HUP0204232A3 (en) 2006-01-30
IL150480A (en) 2007-12-03
CA2400155C (en) 2009-09-15
CZ20022875A3 (cs) 2003-02-12
ES2206403T3 (es) 2004-05-16
JP2003530321A (ja) 2003-10-14
AR029471A1 (es) 2003-07-02
SK287375B6 (sk) 2010-08-09
HK1051856A1 (en) 2003-08-22
EP1259513A2 (de) 2002-11-27
CN1183135C (zh) 2005-01-05

Similar Documents

Publication Publication Date Title
DE60100750D1 (de) NEUE KRISTALLINE FORM VON N-[4-[2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO[2,3-d]-PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMINSÄURE UND VERFAHREN FÜR IHRE HERSTELLUNG
CA2296604A1 (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
CL2010000204A1 (es) Compuestos intermediarios derivados de 4 amino-3-metoxibenzamida; compuesto intermediario n-{4-[4-(ciclopropilmetil)piperazin-1-il]ciclohexil}acetamida; compuesto intermediario 2-cloro-7-etil-7,8-dihidro-5-metil-8-(1-metiletil)-6(5h)-pteridinona, útiles en la preparación de dihidropteridinonas sustituidas (divisional sol. 2077-05).
DE60006464D1 (de) Infrarot-empfindliche zusammensetzung und ihre verwendung für die herstellung von druckplattenvorläufern
DE50011035D1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60018940D1 (de) Stahlblech mit hervorragender gratbearbeitbarkeit bei gleichzeitiger hoher ermüdungsfestigeit und verfahren zu dessen herstellung
DE502004007000D1 (de) Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
SK1452000A3 (en) Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
ATE338027T1 (de) Herstellung von iminodiessigsäure-derivaten aus monoethanolamin-substraten
ATE218335T1 (de) Salze der ketosäuren und amine sowie ihre verwendung zur herstellung von medikamenten
DE69813565D1 (de) Substituierte 3,3-diamino-2-propennitrile, ihre herstellung und verwendung
DE60330199D1 (de) Verfahren zur Herstellung von n1-(2-pyridyl)-1,2-Propandiaminsulfamidsäure und ihre Verwendung zur Herstellung von biologisch aktiven Piperazinen
RU94003397A (ru) Производные 2-/4-(4-азолилбутил)-1-пиперазинил/-пиримидина, способ их получения и фармацевтическая композиция на их основе
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten
ITMI20002186A0 (it) Processo per la produzione dell'acido tiottico racemo
NO20043988L (no) Fremgangsmate for fremstilling av chirale 1,4-substituerte piperaziner
FI20040352L (fi) Menetelmä 4-(3-syaanifenyyli)-trifluorimetyyli-5-okso-1,4,5,6,7,8-heksahydrokinoliini-3-karboksyylihapon valmistamiseksi
ATE300531T1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen
DE69800092D1 (de) Substituierte 4-(6-fluor-[1H]-indol-3-yl)1,2,3,6-Tetrahydropyridin-Derivate für die Behandlung von ZNS-Störungen
DE50206070D1 (de) Verfahren zur Herstellung von copolymeren hydrophob modifizierten Polyglutaminsäurederivaten und ihre Verwendung
WO2003045917A3 (en) Ccr-3 receptor antagonists vii
DE69707114D1 (de) 3-aryl-r-carboxyalkyl substituierte glutarimide, ihre herstellung durch ringschluss von 4-aryl-4-cyanoheptandicarbonsäuren und ihre verwendung zur herstellung von 3-aryl-3-hydroxyalkylpiperidinen
ITMI20000194A0 (it) Processo per la purificazione di 3-ammino.1,2-propandiolo e 2-ammino-1,3-propandiolo
NO983829D0 (no) Nye substituerte N-metyl-N-(4-(4-(1H-benzimidazol-2-yl)£1,4|diazepan-1-yl)-2-(aryl)butyl)benzamider som er anvendbare for behandling av allergiske sykdommer
WO2003004464A3 (de) Heterozyklische amidderivate und deren verwendung als schädlingsbekämpfungsmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259513

Country of ref document: EP